JP2022542540A - isoQC及び/又はQC酵素の阻害剤としてのN-置換-3,4-(縮合5-環)-5-フェニル-ピロリジン-2-オン化合物 - Google Patents

isoQC及び/又はQC酵素の阻害剤としてのN-置換-3,4-(縮合5-環)-5-フェニル-ピロリジン-2-オン化合物 Download PDF

Info

Publication number
JP2022542540A
JP2022542540A JP2022501167A JP2022501167A JP2022542540A JP 2022542540 A JP2022542540 A JP 2022542540A JP 2022501167 A JP2022501167 A JP 2022501167A JP 2022501167 A JP2022501167 A JP 2022501167A JP 2022542540 A JP2022542540 A JP 2022542540A
Authority
JP
Japan
Prior art keywords
frppo
cancer
independently
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022501167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542540A5 (cg-RX-API-DMAC7.html
Inventor
エバーズ,バスティアン
ブレナン,ポール・イー
Original Assignee
シーニック・イミュノロジー・ヴェンノーツハップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーニック・イミュノロジー・ヴェンノーツハップ filed Critical シーニック・イミュノロジー・ヴェンノーツハップ
Publication of JP2022542540A publication Critical patent/JP2022542540A/ja
Publication of JP2022542540A5 publication Critical patent/JP2022542540A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
JP2022501167A 2019-07-12 2020-07-10 isoQC及び/又はQC酵素の阻害剤としてのN-置換-3,4-(縮合5-環)-5-フェニル-ピロリジン-2-オン化合物 Pending JP2022542540A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19185997.4 2019-07-12
EP19185997 2019-07-12
PCT/EP2020/069630 WO2021009068A1 (en) 2019-07-12 2020-07-10 N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme

Publications (2)

Publication Number Publication Date
JP2022542540A true JP2022542540A (ja) 2022-10-05
JP2022542540A5 JP2022542540A5 (cg-RX-API-DMAC7.html) 2023-07-18

Family

ID=67262155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022501167A Pending JP2022542540A (ja) 2019-07-12 2020-07-10 isoQC及び/又はQC酵素の阻害剤としてのN-置換-3,4-(縮合5-環)-5-フェニル-ピロリジン-2-オン化合物

Country Status (12)

Country Link
US (1) US20230077723A1 (cg-RX-API-DMAC7.html)
EP (1) EP3997091A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022542540A (cg-RX-API-DMAC7.html)
KR (1) KR20220054293A (cg-RX-API-DMAC7.html)
CN (1) CN114466849B (cg-RX-API-DMAC7.html)
AU (1) AU2020312647A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000505A8 (cg-RX-API-DMAC7.html)
CA (1) CA3147154A1 (cg-RX-API-DMAC7.html)
IL (1) IL289784A (cg-RX-API-DMAC7.html)
MX (1) MX2022000521A (cg-RX-API-DMAC7.html)
PH (1) PH12022550079A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021009068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717089A3 (en) 2021-08-02 2026-06-24 Syngenta Crop Protection AG Microbiocidal pyrazole derivatives
AU2022203580A1 (en) * 2021-09-17 2023-04-06 Academia Sinica Methods of Increasing Cell Phagocytosis
EP4447682A1 (en) 2021-12-17 2024-10-23 Syngenta Crop Protection AG Microbiocidal pyrazole derivatives
TW202430514A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
PY2403614A (es) 2023-01-27 2025-09-11 Syngenta Crop Protection Ag Derivados de pirazol microbiocidas
PY2404467A (es) 2023-02-01 2025-03-31 Syngenta Crop Protection Ag Composiciones fungicidas
EP4455142A1 (en) 2023-04-26 2024-10-30 Scenic Immunology B.V. Novel inhibitor of qpctl and/or qc
PY2447478A (es) 2023-06-14 2025-03-18 Syngenta Crop Protection Ag Composiciones fungicidas
WO2025114167A1 (en) 2023-11-28 2025-06-05 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
AR134999A1 (es) 2024-02-02 2026-05-20 Syngenta Crop Protection Ag Derivados de pirazol microbiocidas
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025224308A1 (en) * 2024-04-25 2025-10-30 Scenic Immunology B.V. Qpctl inhibitors
WO2026022173A1 (en) 2024-07-26 2026-01-29 Syngenta Crop Protection Ag Microbiocidal pyrazole compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502006A (ja) * 2008-09-04 2012-01-26 プロビオドルグ エージー 新規の阻害剤
JP2016520117A (ja) * 2013-05-27 2016-07-11 ノバルティス アーゲー ピラゾロピロリジン誘導体および疾患の処置におけるその使用
JP2016520118A (ja) * 2013-05-28 2016-07-11 ノバルティス アーゲー Bet阻害剤としてのピラゾロ−ピロリジン−4−オン誘導体および疾患の処置におけるその使用
WO2019022600A1 (en) * 2017-07-24 2019-01-31 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502006A (ja) * 2008-09-04 2012-01-26 プロビオドルグ エージー 新規の阻害剤
JP2016520117A (ja) * 2013-05-27 2016-07-11 ノバルティス アーゲー ピラゾロピロリジン誘導体および疾患の処置におけるその使用
JP2016520118A (ja) * 2013-05-28 2016-07-11 ノバルティス アーゲー Bet阻害剤としてのピラゾロ−ピロリジン−4−オン誘導体および疾患の処置におけるその使用
WO2019022600A1 (en) * 2017-07-24 2019-01-31 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47

Also Published As

Publication number Publication date
EP3997091A1 (en) 2022-05-18
MX2022000521A (es) 2022-06-14
PH12022550079A1 (en) 2023-04-12
BR112022000505A2 (pt) 2022-03-22
BR112022000505A8 (pt) 2022-04-12
CN114466849A (zh) 2022-05-10
CN114466849B (zh) 2024-07-12
AU2020312647A1 (en) 2022-02-24
KR20220054293A (ko) 2022-05-02
WO2021009068A1 (en) 2021-01-21
US20230077723A1 (en) 2023-03-16
IL289784A (en) 2022-03-01
CA3147154A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CN114466849B (zh) 作为isoqc和/或qc酶的抑制剂的n-取代的-3,4-(稠合5-环)-5-苯基-吡咯烷-2-酮化合物
JP7005582B2 (ja) ブルトン型チロシンキナーゼ(btk)インヒビターとしての多フルオロ置換化合物
EP3642198B1 (en) Small molecule modulators of human sting
EP3661921B1 (en) Selective inhibitors of nlrp3 inflammasome
JP7821851B2 (ja) 抗ウイルス性ピリドピラジンジオン化合物
CN106905324B (zh) 具有咪唑并吡嗪酮骨架的pde9抑制剂
CA2897843C (en) Pyrazolopyrimidine compounds
JP2023524018A (ja) Il-17の調節因子としてのイミダゾリダジン
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
AU2021389180A9 (en) Heteroaryl carboxamide compound
MD3831833T2 (ro) Procedee pentru prepararea unui inhibitor PI3K
CN120322430A (zh) Pcsk9抑制剂及其使用方法
JP2021500340A (ja) PI3K−γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体
KR20230016219A (ko) Il-17a 조절제
KR20230021121A (ko) Gpr65의 조절제로서 n-페닐아미노카보닐 피리디노-, 피리미디노 및 벤조-트로판
TW200823212A (en) Kinase inhibitors
CN116874466A (zh) 用作ccr6抑制剂的n-取代二氧代环丁烯基氨基-3-羟基-吡啶甲酰胺
IL293107A (en) Adenosine receptor antagonist compounds
WO2024026424A1 (en) Quinazolinone derivatives as and related uses
CN107266405A (zh) 用于制备c‑fms激酶抑制剂的方法
EP4455142A1 (en) Novel inhibitor of qpctl and/or qc
CN120344515A (zh) Pcsk9抑制剂及其使用方法
HK40029530B (en) Small molecule modulators of human sting
HK40029530A (en) Small molecule modulators of human sting
HK40069881B (en) Antiviral pyrazolopyridinone compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230707

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250114